June 21, 2026
Shot through with drama
FDA advisors unanimously vote to approve Moderna's mRNA after agency drama
After a messy FDA fight, commenters cheer science’s comeback and roast the confusing headline
TLDR: FDA advisers unanimously backed Moderna’s new mRNA flu shot after earlier agency pushback, a sign the vaccine may move closer to approval. Commenters mostly celebrated experts winning out, while others mocked the confusing headline and eagerly asked about a future combo flu/COVID shot.
The official news is big: an outside panel advising the US Food and Drug Administration voted 9–0 to back Moderna’s new seasonal flu shot made with the same mRNA method used in its COVID vaccines. This comes after earlier agency drama, when a Trump appointee reportedly tried to stop the vaccine from even being reviewed. In studies, the shot appeared to work better than standard flu vaccines for older adults, and the safety results were generally reassuring. But in the comments, readers were less interested in the committee acronym soup and more interested in one thing: is science finally getting the steering wheel back?
That’s where the mood got spicy. One of the strongest reactions was blunt relief, with commenters calling this “one step toward putting science back in charge.” Another went full scorched earth, raging that expert judgment has been pushed aside for “podcasters and political sycophants,” turning the thread into a mini culture-war bonfire. Meanwhile, several readers were hilariously stuck on a simpler complaint: the headline confused people. More than one commenter basically yelled, “Guys, say it’s a flu vaccine!” Others were already dreaming ahead, asking whether this is the combo flu/COVID shot and joking about the future luxury of not needing two sore arms. So yes, the vote was unanimous — but the comments still found room for drama, pedantry, and a little vaccine wish-list energy. Classic internet.
Key Points
- •FDA advisors voted 9–0 to support approval of Moderna’s seasonal mRNA flu vaccine.
- •The vaccine under review is Moderna’s mRNA-1010, branded as mFlusiva.
- •The article says a Trump appointee had previously tried to prevent the vaccine from being reviewed.
- •A Phase 3 trial in more than 40,000 adults aged 50 and older found the vaccine was about 27 percent more effective than a standard flu shot.
- •A separate Phase 3 trial in nearly 3,000 adults aged 65 and older found stronger immune responses than a high-dose flu vaccine, and the article says the safety profile was generally good.